On Wednesday, Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), lost -0.38% to $152.66.
Alexion Pharmaceuticals, declared that researchers presented new data from the extension phase of an ongoing, open-label Phase 2 study in children with hypophosphatasia (HPP) who were treated with Strensiq (asfotase alfa) for at least five years (n=12, ages five to 12 years at study entry). In this study, children treated with Strensiq practiced noteworthyhealing of HPP-related skeletal manifestations and improvements in physical function within three to six months from treatment onset, which were sustained through five years of treatment. These data were presented in an oral session at the 2015 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Seattle. In a separate analysis presented at ASBMR, clinically noteworthyimprovements in functional mobility contrast to historical controls were observed in patients with juvenile-onset HPP who were treated with Strensiq in the ongoing, open-label Phase 2 study.
HPP is a genetic and progressive metabolic disease in which patients experience devastating effects on multiple systems of the body, leading to debilitating or life-threatening complications.3 It is an ultra-rare disease, which is defined as a disease that affects fewer than 20 patients per one million in the general population.4 HPP is characterized by low alkaline phosphatase (ALP) activity and defective bone mineralization that can lead to deformity of bones and other skeletal abnormalities, in addition to systemic complications such as profound muscle weakness, seizures, pain, and respiratory failure leading to premature death in infants.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease.
Shares of Norwegian Cruise Line Holdings Ltd (NASDAQ:NCLH), declined -4.26% to $56.82, during its last trading session.
Norwegian Cruise Line will introduce the first purpose-built ship customized for the China market in 2017, Norwegian Cruise Line Holdings Ltd. (NCLH) CEO Frank Del Rio declared recently during the CruiseWorld China summit in Shanghai. Presently under construction, the new ship is designed specifically for the China market with accommodations, cuisine and onboard experiences that cater to the unique vacation preferences of Chinese guests.
“Our new purpose-built ship for China will have characteristics that are authentic to Norwegian Cruise Line and yet distinctively Chinese in all of its sensibility,” said Del Rio. “With this new ship, Norwegian will unquestionably offer our Chinese guests a superior product and introduce a new standard of innovation and excellence into the marketplace, with an unrivaled level of customization for the Chinese consumer. It will perfectly suit what modern Chinese travelers value from an upscale cruise experience.”
The new ship will be the second of Norwegian Cruise Line’s Breakaway Plus class and features the line’s unique style of cruising known as Freestyle Cruising. Aboard NCL ships, Chinese guests will indulge in a resort-style vacation experience, with the freedom and flexibility to joyfully spend time doing whatever they wish, from enjoying world-class entertainment to fine Mandarin, Cantonese and Continental dining; from duty-free luxury shopping to participating in any number of incredible first-at-sea activities onboard; all on their own time plan.
Norwegian Cruise Line Holdings Ltd., a cruise line operator, through its auxiliaries, provides cruise experiences for travelers with various itineraries. It offers cruises ranging from 1 day to 180 days. The company’s distribution channel comprises independent travel agents, wholesalers, and tour operators.
Finally, AstraZeneca plc (ADR) (NYSE:AZN), ended its last trade with 0.67% gain, and closed at $31.51.
AstraZeneca, presented results from an ongoing observational study, SENTINEL, at the IDWeek 2015 annual scientific meeting in San Diego, California. SENTINEL was designed to characterize RSV-confirmed hospitalizations among US preterm infants born at 29-35 weeks gestation who did not receive immunoprophylaxis during the 2014-2015 RSV season. In July 2014, new guidance was published that recommended against the use of immunoprophylaxis for respiratory syncytial virus (RSV) in preterm infants born at 29-35 weeks gestation who do not have chronic lung disease.
The study results confirmed that among preterm infants 29-35 weeks gestation who did not receive immunoprophylaxis, RSV disease can be severe, often resulting in intensive care unit (ICU) admission and the need for mechanical ventilation (MV).
“RSV disease is the most common serious infection preterm infants will face in the first months of life,” said lead investigator Dr. Leonard Krilov, pediatric infectious disease specialist, Winthrop-University Hospital. “The SENTINEL study confirms that preterm infants born at 29-35 weeks gestation commonly have serious complications when hospitalized with RSV disease.”
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company’s medicines comprise Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
